Search results
Results from the WOW.Com Content Network
The Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM) generally known as the Indian Patent Office, is an agency under the Department for Promotion of Industry and Internal Trade which administers the Indian law of Patents, Designs and Trade Marks. [1] [2]
"Indian trademark law" statutorily protects trademarks as per the Trademark Act, 1999 and also under the common law remedy of passing off. [9] Statutory protection of trademark is administered by the Controller General of Patents, Designs and Trade Marks, a government agency which reports to the Department of Industrial Policy and Promotion (DIPP), under the Ministry of Commerce and Industry.
The Comptroller General of Patents, Designs and Trade Marks is the head of the UK Intellectual Property Office or Patent Office. The Comptroller and Auditor General is head of the National Audit Office, and is the successor of the former Comptroller General of the Exchequer and the former Commissioners of Audit.
The Department for Promotion of Industry and Internal Trade (DPIIT) is a central government department under the Ministry of Commerce and Industry in India. It is responsible for formulation and implementation of promotional and developmental measures for growth of the industrial sector, keeping in view the national priorities and socio-economic objectives.
Directorate General of Trade Remedies (DGTR) Directorate General of Supplies and Disposals (DGS&D) Office of the Economic Adviser; Directorate General of Commercial Intelligence and Statistics (DGCI&S) Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM) Indian Patent Office; Special Economic Zones
In India, compulsory license may be issued by the Controller General of Patents, Designs and Trade Marks under section 84(1) of The Patents Act, 1970, if: [24] The reasonable requirements of the public with respect to the patented invention have not been satisfied, or,
A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought ...
The delay was attributed by spokesmen for the Patent Office to a combination of a sudden increase in business method patent filings after the 1998 State Street Bank decision, the unfamiliarity of patent examiners with the business and financial arts (e.g., banking, insurance, stock trading etc.), and the issuance of a number of controversial ...